R
Respirationsorganer
Relevante links
Langtidsvirkende β2-agonist i kombination med langtidsvirkende antikolinergika (LABA/LAMA)
R03AL
Ved KOL forbedrer kombinationen LABA/LAMA lungefunktionen mere end enkeltstofferne hver for sig (2530) og kombinationen er desuden effektiv til at forebygge eksacerbationer (2529) (3029).
Langtidsvirkende β2-agonist i kombination med langtidsvirkende antikolinergika (LABA/LAMA) - inhalationsdevices
|
Device |
Styrker |
Antal doser |
Billigste DDD* |
Handelsnavne |
Kommentarer |
|
Formoterol/aclidinium |
|||||
|---|---|---|---|---|---|
|
|
12 μg/ 340 μg |
60 |
13,73 |
Holdbar i 2 måneder efter anbrud af folien. Inhalatoren har dosistæller. |
|
|
Formoterol/glycopyrronium |
|||||
|
|
5 μg/ 7,2 μg |
120 |
15,84 |
Holdbar i 3 måneder efter anbrud af folien. Inhalatoren har dosistæller. |
|
|
Indacaterol/glycopyrronium |
|||||
|
|
85 μg/ 43 μg |
1 |
14,74 |
Der skal indsættes kapsel i inhalatoren. |
|
|
Olodaterol/tiotropium |
|||||
|
|
2,5 μg/ 2,5 μg |
30 |
15,91 |
Patronen er holdbar i 3 måneder efter anbrud. En markør angiver, hvornår inhalatoren er tom. |
|
|
Vilanterol/umeclidinium |
|||||
|
|
22 μg/ 55 μg |
30 |
12,50 |
Holdbar i 6 uger efter anbrud af bakken. Inhalatoren har dosistæller. |
|
* Priserne er gældende pr. mandag den 15. maj 2023. Se endvidere WHO vedr. DDD-værdier for kombinationsmidler til inhalation: List of DDDs combined products
Præparater
| Indholdsstof | Navn og firma | Dispform og styrke | Pakning | Pris enh. | Pris DDD |
|---|---|---|---|---|---|
| Umeclidinium Vilanterol |
Anoro Ellipta® GSK Pharma
|
inhalationspulver 55 mikrg / 22 mikrg | 30 doser | 12,87 | |
| Umeclidinium Vilanterol |
Anoro Ellipta® GSK Pharma
|
inhalationspulver 55 mikrg / 22 mikrg | 30 doser (Orifarm) | 13,50 | |
| Umeclidinium Vilanterol |
Anoro Ellipta® GSK Pharma
|
inhalationspulver 55 mikrg / 22 mikrg | 90 doser (3 x 30) | 12,50 | |
| Umeclidinium Vilanterol |
Anoro Ellipta® GSK Pharma
|
inhalationspulver 55 mikrg / 22 mikrg | 90 doser (3 x 30) (Medartuum) | 13,29 | |
| Umeclidinium Vilanterol |
Anoro Ellipta® GSK Pharma
|
inhalationspulver 55 mikrg / 22 mikrg | 90 doser (3 x 30) (Orifarm) | 13,32 | |
| Formoterol Glycopyrroniumbromid |
Bevespi Aerosphere AstraZeneca
|
inhalationsspray, suspension 7,2+5,0 mikrogram | 120 doser | 4,05 | |
| Formoterol Glycopyrroniumbromid |
Bevespi Aerosphere AstraZeneca
|
inhalationsspray, suspension 7,2+5,0 mikrogram | 120 doser (2care4) | 4,06 | |
| Formoterol Glycopyrroniumbromid |
Bevespi Aerosphere AstraZeneca
|
inhalationsspray, suspension 7,2+5,0 mikrogram | 120 doser (Orifarm) | 4,07 | |
| Formoterol Glycopyrroniumbromid |
Bevespi Aerosphere AstraZeneca
|
inhalationsspray, suspension 7,2+5,0 mikrogram | 360 doser (3 x 120) (2care4) | 3,97 | |
| Formoterol Glycopyrroniumbromid |
Bevespi Aerosphere AstraZeneca
|
inhalationsspray, suspension 7,2+5,0 mikrogram | 360 doser (3 x 120) | 3,96 | |
| Formoterol Glycopyrroniumbromid |
Bevespi Aerosphere AstraZeneca
|
inhalationsspray, suspension 7,2+5,0 mikrogram | 360 doser (3 x 120) (Orifarm) | 4,47 | |
| Formoterol Glycopyrroniumbromid |
Bevespi Aerosphere AstraZeneca
|
inhalationsspray, suspension 7,2+5,0 mikrogram | 360 doser (3 x 120) (Abacus) | 3,96 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 60 doser | 7,44 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 60 doser (Orifarm) | 7,43 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 60 doser (Abacus) | 8,30 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 60 doser (2care4) | 7,45 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 180 doser (3 x 60) | 7,41 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 180 doser ( 3 x 60) (2care4) | 6,91 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 180 doser (3 x 60) (Orifarm) | 6,87 | |
| Aclidinium Formoterol |
Duaklir Genuair Zentiva
|
inhalationspulver 340 + 12 mikrog. | 180 doser (3 x 60) (Abacus) | 6,98 | |
| Olodaterol Tiotropium |
Spiolto® Respimat® Boehringer Ingelheim
|
inhalationsvæske, opløsning 2,5+2,5 mikrogram | 30 doser (refill) | 16,50 | |
| Olodaterol Tiotropium |
Spiolto® Respimat® Boehringer Ingelheim
|
inhalationsvæske, opløsning 2,5+2,5 mikrogram | 30 doser+device (flergang) | 16,82 | |
| Olodaterol Tiotropium |
Spiolto® Respimat® Boehringer Ingelheim
|
inhalationsvæske, opløsning 2,5+2,5 mikrogram | 3 x 30 doser (refill) | 15,91 | |
| Olodaterol Tiotropium |
Spiolto® Respimat® Boehringer Ingelheim
|
inhalationsvæske, opløsning 2,5+2,5 mikrogram | 3x30 doser+device (flergang) | 16,19 | |
| Olodaterol Tiotropium |
Spiolto® Respimat® Boehringer Ingelheim
|
inhalationsvæske, opløsning 2,5+2,5 mikrogram | 3x30 doser+device (flergang) | 16,19 | |
| Olodaterol Tiotropium |
Spiolto® Respimat® Boehringer Ingelheim
|
inhalationsvæske, opløsning 2,5+2,5 mikrogram | 3 x 30 doser (refill) | 15,91 | |
| Glycopyrroniumbromid Indacaterol |
Ultibro® Breezhaler® Novartis
|
inhalationspulver, kapsler 85 + 43 mikrogram | 30 stk. (blister)+inh(2care4) | 22,36 | |
| Glycopyrroniumbromid Indacaterol |
Ultibro® Breezhaler® Novartis
|
inhalationspulver, kapsler 85 + 43 mikrogram | 30 stk. (blister)+inh(Orifarm) | 15,17 | |
| Glycopyrroniumbromid Indacaterol |
Ultibro® Breezhaler® Novartis
|
inhalationspulver, kapsler 85 + 43 mikrogram | 30 stk. (blister) + inhalator | 15,11 | |
| Glycopyrroniumbromid Indacaterol |
Ultibro® Breezhaler® Novartis
|
inhalationspulver, kapsler 85 + 43 mikrogram | 90 stk. (blister) + inhalator | 14,74 | |
| Glycopyrroniumbromid Indacaterol |
Xoterna Breezhaler® Novartis
Udgået
01.05.2023
|
inhalationspulver, kapsler 85 + 43 mikrogram | 90 stk. (blister)+inh.(Orifarm |
Referencer
3029. Wedzicha JA, Banerji D, Chapman KR et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016; , http://www.nejm.org/doi/full/10.1056/NEJMoa1516385?rss=mostViewed&#t=article (Lokaliseret 10. maj 2023)
2530. Decramer M, Anzueto A, Kerwin E et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014; 2(6):472-86, http://www.ncbi.nlm.nih.gov/pubmed/24835833 (Lokaliseret 2. maj 2023)
2529. Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013; 1(3):199-209, http://www.ncbi.nlm.nih.gov/pubmed/24429126 (Lokaliseret 2. maj 2023)
